Comparing CTI Industries (CTIB) & Veru (VERU)

CTI Industries (NASDAQ:CTIB) and Veru (NASDAQ:VERU) are both small-cap industrial products companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Profitability

This table compares CTI Industries and Veru’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
CTI Industries -2.32% -7.18% -1.86%
Veru -130.26% -38.09% -29.78%



Valuation & Earnings

This table compares CTI Industries and Veru’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
CTI Industries $56.24 million 0.25 -$1.60 million N/A N/A
Veru $13.66 million 5.18 -$6.61 million ($0.25) -5.12

CTI Industries has higher revenue and earnings than Veru.

Institutional and Insider Ownership

4.8% of CTI Industries shares are owned by institutional investors. Comparatively, 5.2% of Veru shares are owned by institutional investors. 50.0% of CTI Industries shares are owned by insiders. Comparatively, 37.0% of Veru shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations for CTI Industries and Veru, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CTI Industries 0 0 0 0 N/A
Veru 0 0 3 0 3.00

Veru has a consensus target price of $7.50, suggesting a potential upside of 485.94%. Given Veru’s higher probable upside, analysts clearly believe Veru is more favorable than CTI Industries.

Volatility & Risk

CTI Industries has a beta of 0.48, suggesting that its share price is 52% less volatile than the S&P 500. Comparatively, Veru has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500.

Summary

CTI Industries beats Veru on 6 of the 11 factors compared between the two stocks.

CTI Industries Company Profile

CTI Industries Corporation develops, produces, and distributes consumer and film products for commercial and industrial uses in the United States, the United Kingdom, Europe, and Mexico. The company offers novelty products, including foil balloons; latex balloons under the Partyloons name; balloon products, which include punch balls, water bombs, and Animal Twisties; and other inflatable toy items. It also provides vacuum sealable bags and rolls of film for household storage under the Ziploc brand; vacuum sealing machines under the Ziploc name; and valved resealable bags for vacuum storage use under the Zipvac brand name. In addition, the company offers packaging films and custom film products for food, and other commercial and packaging applications; produces and distributes home organization and container products; assembles and sells Candy Blossom product line; and distribute party goods. It primarily serves various retail outlets, including general merchandise stores, discount and drugstore chains, grocery chains, card and gift shops, and party goods stores, as well as florists and balloon decorators. The company sells its products directly, as well as through a network of distributors and wholesalers, and independent sales representatives. CTI Industries Corporation was founded in 1975 and is headquartered in Lake Barrington, Illinois.

Veru Company Profile

Veru Inc. operates as a urology and oncology biopharmaceutical company. The company operates through two segments, Commercial; and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation. The company's urology drug candidates include Tamsulosin delayed release sachet and Tamsulosin XR capsules that are under bioequivalence study for the treatment of benign prostatic hyperplasia; and Solifenacin delayed release granules, which are under bioequivalence study for the treatment of overactive bladder. Its urology drug candidates also comprise Tadalafil-Finasteride combination capsules that are under bioequivalence study for the treatment of men with lower urinary tract symptoms and enlarged prostate; VERU-944, which is in Phase II clinical trial for the treatment of hot flashes in men on prostate cancer hormonal therapies; and VERU-722 that is in Phase II clinical trial for the treatment of male infertility caused by testicular dysfunction. The company's oncology drug candidate is VERU-111, a novel oral alpha and beta tubulin inhibitor, which is under preclinical study for the treatment of metastatic prostate, breast, endometrial, ovarian, and other cancers. It also develops VERU-111/VERU-112, a novel oral agent targeting colchicine binding site that is under preclinical study for the treatment of gout and familial mediterranean fever. Veru Inc. serves agencies, non-government organizations, ministries of health, and other governmental agencies through distributors and retailers primarily in the United States, Brazil, Spain, France, and the United Kingdom. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was founded in 1896 and is headquartered in Miami, Florida.

Receive News & Ratings for CTI Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply